Lytix Biopharma

Norway · Biotechnology

Lytix Biopharma is a clinical-stage biotechnology company based in Norway, focused on developing novel cancer immunotherapies. The company utilizes a technology platform centered on host-defense peptide-derived molecules that are designed to selectively kill cancer cells while activating the patient’s immune system. This approach aims to enhance treatment efficacy and improve patient outcomes in cancer care. The company is advancing its pipeline through clinical trials, with plans for Phase III development supported by strong clinical momentum. Lytix Biopharma's investigational therapies leverage tumor-infiltrating lymphocyte (TIL) technology to boost the immune response against various cancer types. The company primarily serves the oncology market, targeting cancer patients and healthcare providers involved in cancer treatment.